title: Vaporization of prostates of > or =80 mL using a potassium-titanyl-phosphate laser: midterm-results and comparison with prostates of <80 mL.
abstract: OBJECTIVE
  To compare the safety and outcome of potassium-titanyl-phosphate (KTP) Greenlight (Laserscope, AMS, Minnetonka, MN, USA) vaporization for treating benign prostatic hyperplasia (BPH) in prostates of > or =80 vs <80 mL.
  
  
  METHODS
  In all, 204 consecutive patients were enrolled into this prospective study; 31 were excluded from analysis for various reasons, thus 173 (median age 66.8 years; 39 with prostates of > or =80 mL) were evaluated for maximum urinary flow rate (Q(max)), postvoid residual urine (PVR), the International Prostate Symptom Score (IPSS), and quality-of-life (QoL) score. The median follow-up was 11.7 months. Of the 173 men, 26.6% were anaesthesiological high-risk patients and 32.4% took anticoagulants.
  
  
  RESULTS
  The Q(max) improved in prostates of > or =80 mL from 6.9 mL/s before to 15.3 mL/s immediately after catheter removal, and 23.4 mL/s after 3 months (P < 0.001). The improvement was similar to that in smaller prostates. There were equally effective changes in PVR (P < 0.001). The IPSS decreased from 19.0 before to 7.0, 4.0 and 5.5 at 3, 6 and 12 months after surgery (P < 0.001). Changes did not differ from those in smaller glands. The results were similar for QoL (P < 0.001). During surgery there was no major bleeding and no transurethral resection syndrome. There was acute urinary retention after catheter removal in 10.4% of men; 4.6% developed urinary tract infections, whereas the rate was higher in men with larger prostates (10.3%). The re-operation rate was higher in men with larger prostates, at 23.1% vs 10.4% (P = 0.09). CONCLUSION KTP laser vaporization is a safe and effective procedure for surgically treating BPH. The functional outcome in larger prostates is similar to that in smaller glands, but there was a serious trend to a higher re-operation rate in men with larger prostates.
authors.affiliation: Department of Urology, Medical Center, University of Heidelberg, Germany. Jesco.Pfitzenmaier@med.uniheidelberg.de
authors.forename: Jesco
authors.initials: J
authors.lastname: Pfitzenmaier
authors.forename: Christian
authors.initials: C
authors.lastname: Gilfrich
authors.forename: Maria
authors.initials: M
authors.lastname: Pritsch
authors.forename: Daniela
authors.initials: D
authors.lastname: Herrmann
authors.forename: Stephan
authors.initials: S
authors.lastname: Buse
authors.forename: Axel
authors.initials: A
authors.lastname: Haferkamp
authors.forename: Nenad
authors.initials: N
authors.lastname: Djakovic
authors.forename: Sascha
authors.initials: S
authors.lastname: Pahernik
authors.forename: Markus
authors.initials: M
authors.lastname: Hohenfellner
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D006801:Humans; D053844:Lasers, Solid-State / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009929:Organ Size; D011183:Postoperative Complications / Q000209:etiology; D011446:Prospective Studies; D011467:Prostate / Q000473:pathology / Q000601:surgery*; D011468:Prostatectomy / Q000379:methods*; D011470:Prostatic Hyperplasia / Q000473:pathology / Q000601:surgery*; D011788:Quality of Life; D012086:Reoperation; D012307:Risk Factors; D016896:Treatment Outcome; D014835:Volatilization